(ZTS) Zoetis - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98978V1035

Vaccines, Parasiticides, Diagnostics, Dermatology, Anti-Infectives

Stock: Pharmaceuticals
Age 13y

MCap 55,243m
Avg Vol 4.36M (547M USD)

Beta 0.616
Volatility 23.77%

EPS (Earnings per Share)

EPS CAGR: -46.76%
EPS Trend: -16.6%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 5.45%
Rev. Trend: 92.3%

Last SUE: -0.14
Qual. Beats: 0

Dividends

Dividend Yield	1.76%
Yield on Cost 5y	1.32%
Yield CAGR 5y	18.92%
Payout Consistency	100.0%
Payout Ratio	32.8%

Risk via 5d forecast
Volatility	23.8%
Value at Risk 5%th	36.9%
Relative Tail Risk	-5.58%

Reward TTM
Sharpe Ratio	-0.97
Alpha	-35.28
CAGR/Max DD	-0.20

Character TTM
Hurst Exponent	0.721
Beta	0.616
Beta Downside	0.545

Drawdowns 3y
Max DD	40.89%
Mean DD	13.65%
Median DD	11.88%

Description: ZTS Zoetis December 03, 2025

Zoetis Inc. (NYSE: ZTS) develops, manufactures, and markets a broad portfolio of animal-health products-including medicines, vaccines, diagnostics, biodevices, genetic tests, and precision-health solutions-for livestock (cattle, swine, poultry, fish, sheep) and companion animals (dogs, cats, horses). Its offerings span parasiticides, anti-infectives, dermatology, pain-management, and point-of-care diagnostics, and it sells primarily to veterinarians, livestock producers, and pet owners. The company also partners with Blacksmith Medicines to explore novel animal-health antibiotics.

Key recent data points: • FY 2023 revenue reached $7.6 billion, with a 9 % YoY increase driven by strong growth in companion-animal vaccines and livestock pharmaceuticals. • The global animal-health market is projected to expand at a CAGR of ~5 % through 2028, underpinned by rising protein demand and higher pet-care spending. • Zoetis’s 2024 guidance anticipates a 6-7 % earnings-per-share growth, supported by its expanding precision-health platform and cost-efficiency initiatives in manufacturing.

For a deeper, data-driven look at ZTS’s valuation and risk profile, you may find ValueRay’s analyst tools helpful.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income: 2.65b TTM > 0 and > 6% of Revenue
FCF/TA: 0.15 > 0.02 and ΔFCF/TA -1.30 > 1.0
NWC/Revenue: 50.82% < 20% (prev 50.04%; Δ 0.78% < -1%)
CFO/TA 0.19 > 3% & CFO 2.92b > Net Income 2.65b
Net Debt (5.19b) to EBITDA (4.05b): 1.28 < 3
Current Ratio: 3.64 > 1.5 & < 3
Outstanding Shares: last quarter (443.2m) vs 12m ago -2.27% < -2%
Gross Margin: 70.63% > 18% (prev 0.68%; Δ 6994 % > 0.5%)
Asset Turnover: 63.67% > 50% (prev 63.75%; Δ -0.07% > 0%)
Interest Coverage Ratio: 15.42 > 6 (EBITDA TTM 4.05b / Interest Expense TTM 231.0m)

Altman Z'' 7.99

A: 0.32 (Total Current Assets 6.58b - Total Current Liabilities 1.81b) / Total Assets 15.16b
B: 0.90 (Retained Earnings 13.59b / Total Assets 15.16b)
C: 0.24 (EBIT TTM 3.56b / Avg Total Assets 14.76b)
D: 1.31 (Book Value of Equity 12.78b / Total Liabilities 9.76b)
Altman-Z'' Score: 7.99 = AAA

Beneish M -3.02

DSRI: 1.06 (Receivables 1.54b/1.41b, Revenue 9.40b/9.15b)
GMI: 0.97 (GM 70.63% / 68.49%)
AQI: 0.97 (AQ_t 0.31 / AQ_t-1 0.32)
SGI: 1.03 (Revenue 9.40b / 9.15b)
TATA: -0.02 (NI 2.65b - CFO 2.92b) / TA 15.16b)
Beneish M-Score: -3.02 = AA

ValueRay F-Score (Strict, 0-100) 83.40

1. Piotroski: 6.50pt
2. FCF Yield: 3.71%
3. FCF Margin: 23.84%
4. Debt/Equity: 1.35
5. Debt/Ebitda: 1.28
6. ROIC - WACC: 17.54%
7. RoE: 53.56%
8. Revenue Trend: 92.34%
9. EPS Trend: -16.56%

What is the price of ZTS shares?

As of January 25, 2026, the stock is trading at USD 124.05 with a total of 3,339,659 shares traded.
Over the past week, the price has changed by -0.06%, over one month by +0.84%, over three months by -14.60% and over the past year by -24.62%.

Is ZTS a buy, sell or hold?

Zoetis has received a consensus analysts rating of 4.26. Therefore, it is recommended to buy ZTS.

Strong Buy: 10
Buy: 4
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ZTS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	158.2	27.5%
Analysts Target Price	158.2	27.5%
ValueRay Target Price	118.5	-4.5%

ZTS Fundamental Data Overview January 21, 2026

P/E Trailing = 20.9496
P/E Forward = 18.9394
P/S = 5.8788
P/B = 10.1764
P/EG = 2.3398
Revenue TTM = 9.40b USD
EBIT TTM = 3.56b USD
EBITDA TTM = 4.05b USD
Long Term Debt = 7.07b USD (from longTermDebt, last quarter)
Short Term Debt = 1.35b USD (from shortTermDebt, last fiscal year)
Debt = 7.27b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.19b USD (from netDebt column, last quarter)
Enterprise Value = 60.44b USD (55.24b + Debt 7.27b - CCE 2.08b)
Interest Coverage Ratio = 15.42 (Ebit TTM 3.56b / Interest Expense TTM 231.0m)
EV/FCF = 26.98x (Enterprise Value 60.44b / FCF TTM 2.24b)
FCF Yield = 3.71% (FCF TTM 2.24b / Enterprise Value 60.44b)
FCF Margin = 23.84% (FCF TTM 2.24b / Revenue TTM 9.40b)
Net Margin = 28.21% (Net Income TTM 2.65b / Revenue TTM 9.40b)
Gross Margin = 70.63% ((Revenue TTM 9.40b - Cost of Revenue TTM 2.76b) / Revenue TTM)
Gross Margin QoQ = 71.54% (prev 72.28%)
Tobins Q-Ratio = 3.99 (Enterprise Value 60.44b / Total Assets 15.16b)
Interest Expense / Debt = 0.80% (Interest Expense 58.0m / Debt 7.27b)
Taxrate = 18.71% (166.0m / 887.0m)
NOPAT = 2.90b (EBIT 3.56b * (1 - 18.71%))
Current Ratio = 3.64 (Total Current Assets 6.58b / Total Current Liabilities 1.81b)
Debt / Equity = 1.35 (Debt 7.27b / totalStockholderEquity, last quarter 5.40b)
Debt / EBITDA = 1.28 (Net Debt 5.19b / EBITDA 4.05b)
Debt / FCF = 2.32 (Net Debt 5.19b / FCF TTM 2.24b)
Total Stockholder Equity = 4.95b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.96% (Net Income 2.65b / Total Assets 15.16b)
RoE = 53.56% (Net Income TTM 2.65b / Total Stockholder Equity 4.95b)
RoCE = 29.64% (EBIT 3.56b / Capital Employed (Equity 4.95b + L.T.Debt 7.07b))
RoIC = 24.85% (NOPAT 2.90b / Invested Capital 11.65b)
WACC = 7.31% (E(55.24b)/V(62.52b) * Re(8.19%) + D(7.27b)/V(62.52b) * Rd(0.80%) * (1-Tc(0.19)))
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.85%
[DCF Debug] Terminal Value 82.95% ; FCFF base≈2.27b ; Y1≈2.67b ; Y5≈4.08b
Fair Price DCF = 171.2 (EV 80.63b - Net Debt 5.19b = Equity 75.44b / Shares 440.7m; r=7.31% [WACC]; 5y FCF grow 18.89% → 2.90% )
EPS Correlation: -16.56 | EPS CAGR: -46.76% | SUE: -4.0 | # QB: 0
Revenue Correlation: 92.34 | Revenue CAGR: 5.45% | SUE: -0.14 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.58 | Chg30d=+0.007 | Revisions Net=-2 | Analysts=10
EPS next Year (2026-12-31): EPS=6.79 | Chg30d=-0.006 | Revisions Net=-4 | Growth EPS=+7.1% | Growth Revenue=+5.0%

Additional Sources for ZTS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle